Embecta Corp. — Q1 FY2024 Form 10-Q
Reporting period: Three months ended December 31, 2023, compared with the three months ended December 31, 2022. Embecta is a global medical-device company focused on diabetes care, including pen needles, syringes, safety devices and a digital application.
Financial performance
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Revenue | $277.3 million | $275.7 million | Up 0.6% |
| Gross profit / margin | $185.9 million / 67.0% | $188.8 million / 68.5% | Profit down $2.9 million |
| Operating income | $45.5 million | $88.8 million | Down 48.8% |
| Net income | $20.1 million | $35.2 million | Down 42.9% |
| Diluted EPS | $0.35 | $0.61 | Down 42.6% |
| Operating cash flow | $(13.1) million | $60.4 million | Down $73.5 million |
Revenue was nearly flat: favorable pricing and foreign-exchange effects were partly offset by lower volume and reduced contract-manufacturing sales to BD. U.S. revenue was $148.6 million versus $149.3 million; international revenue was $128.7 million versus $126.4 million. Cost inflation, freight, labor and unfavorable manufacturing variances contributed to lower gross margin. Selling and administrative expense rose 24.0%, research and development expense rose 19.5%, and other operating expenses rose to $29.9 million from $10.3 million.
Cash, debt and liquidity
Cash and cash equivalents were $298.7 million at December 31, 2023, down from $326.5 million at September 30, 2023. Investing cash outflow was $2.7 million, primarily capital expenditures; financing cash outflow was $13.5 million, including $8.6 million of dividends and $2.4 million of debt payments. The operating cash outflow included a $78.6 million increase in trade receivables, which management attributed to Embecta taking over U.S. receivable collections after a BD factoring arrangement ended; management expects to collect these receivables during fiscal 2024 under normal payment terms.
Principal debt outstanding totaled $1,633.4 million: a $933.4 million term loan, $500 million of 5.00% notes and $200 million of 6.75% notes. Reported total debt carrying value was $1,602.4 million, including current debt. The weighted-average cost of total debt was 7.2%; the revolving credit facility had no borrowings. The company reported covenant compliance and stated cash, operating cash flow and available revolving capacity should fund foreseeable requirements. A 100-basis-point rate change would affect annualized term-loan interest expense by approximately $9.3 million.
Significant changes, outlook and risks
- Other operating expenses included approximately $26.4 million of separation and stand-up costs, compared with $9.9 million a year earlier, plus $1.9 million of severance costs. Embecta expects similar separation-related costs in the current year.
- The effective tax rate was (40.6)% versus 37.3%, mainly reflecting a one-time approximately $17.1 million deferred-tax benefit from Swiss tax-law changes. This benefit partly cushioned the earnings decline.
- Research and development investment increased, primarily for the insulin patch-pump platform. Embecta submitted its first FDA 510(k) premarket filing for a proprietary disposable insulin-delivery system in December 2023; clearance and commercialization timing are uncertain.
- Embecta continues to transition from BD-provided systems and services. The U.S. portion of a factoring arrangement ended in November 2023, while certain BD services in a limited set of markets are conditionally extended through November 1, 2024, subject to a supplemental private-letter ruling. The transition and ERP implementation may add cost and execution risk.
- Management reported no material operating or financial impact as of February 9, 2024 from the conflicts in Ukraine and the Middle East, but their future impact remains uncertain. Other risks include pricing pressure, competition and commoditization, changing diabetes treatment practices, supply-chain inflation and disruption, foreign exchange, interest rates, regulation and dependence on key customers and BD arrangements.
- No formal numerical financial guidance is provided in the filing. Management says available liquidity is expected to support operating needs, debt service, dividends and growth opportunities for the foreseeable future.
Important facts for investors to verify
- Whether the substantial receivables increase converts to cash as management expects, and whether operating cash flow normalizes.
- Whether separation, ERP and stand-alone operating costs decline or remain elevated, and whether the transition from BD services proceeds on schedule.
- FDA review progress and potential timing, clearance and commercial prospects for the disposable insulin-delivery system.
- Debt-service capacity and sensitivity to interest rates, given substantial leverage and variable-rate term-loan exposure.
- Customer concentration: three customers represented approximately 40.8% of revenue, and four represented approximately 60.9% of trade receivables.
- The size and development of rebate and other variable-consideration obligations, which were $118.0 million at quarter-end versus $36.4 million at September 30, 2023; quarterly sales deductions were $126.7 million versus $92.6 million.